Embed Size (px)
DESCRIPTION
The conference was attended by approximate 200 experts representing a wide range of views on pharmaceutical policy issues: the pharmaceutical industry, public and private drug plans, government, nonprofit organizations, health professions, and academia. Over 90% of the participants at the conference said that the pharmacare system in Canada needed to be reformed. Data presented here are from audience polling at the Pharmacare 2020 conference held on 26/27 Feb 2013 in Vancouver. Polling was conducted electronically and was strictly voluntary and anonymous. 173 of approximately 200 delegates participated in polling (>80% participation rate). 168 delegates (>80%) answered questions about the sector in which they work. Sector-specific results are not reported for groups with 5 or fewer polling participants (e.g., private insurers and representatives of “other” sectors). The text of some questions and answers has been edited slightly to fit presentation slides. Some percentages do not add up to 100 because of rounding.
Citation preview
Methods• Data presented here are from audience polling at the Pharmacare 2020
conference held on 26/27 Feb 2013 in Vancouver.• Polling was conducted electronically and was strictly voluntary and
anonymous.• 173 of approximately 200 delegates participated in polling (>80%
participation rate).• 168 delegates (>80%) answered questions about the sector in which
they work.• Sector-specific results are not reported for groups with 5 or fewer
polling participants (e.g., private insurers and representatives of “other” sectors).
• The text of some questions and answers has been edited slightly to fit presentation slides.
• Some percentages do not add up to 100 because of rounding.
Rx IndustryHealth
professions Non-profits Public sector Academia Others
11111111
1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 1
N 37 26 14 36 45 10
BC Prairies ON QC Atlantic Other
1111111111 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1 1 11 1 1 1 1 1
N 76 20 60 7 2 3
Which category best describes the sector in which you work?
AllDelegates
AllDelegates
Where do you currently live/work?
Little incentive for Rx innovation
Canadians cannot afford
needed Rx
Too much financial burden
on patients
Little control over Rx
expenditures
Inappropriate prescription drug
useOther / I don’t
know
111
1 1 11 1 11 1 11 1 11 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1
1 1 1 1 1 11 1 1 1 1 11 1 1 1 1 1
% 6 21 13 27 22 11
What do you see as the primary challenge in pharmacare policy today?
AllDelegates
Little incentive for Rx innovation
Canadians cannot afford
needed Rx
Too much financial burden
on patients
Little control over Rx
expenditures
Inappropriate prescription drug
useOther / I don’t
know
1 11 11 11 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 1
% 20 13 7 7 27 27
11111111 11 11 11 11 11 11 1 11 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1 1
% 4 26 9 39 13 9
11111111111111111111111 1 11 1 11 1 11 1 1 1 11 1 1 1 11 1 1 1 1
% 0 57 14 7 14 7
11111 11 11 11 11 11 11 11 11 11 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1 1
% 3 12 9 38 29 9
111 11 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1 11 1 1 1 1
% 2 21 26 30 16 5
Academia
What do you see as the primary challenge in pharmacare policy today?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Incentives for investment and
innovation
Appropriateness of prescribing
and use
Access to needed Rx for all
Canadians
Choice regarding Rx and/or insurance
Equity in the distribution of Rx
costs
Efficiency in management of Rx expenditures
1
11
1
1
1
1
1
11
1
1
11 1 1
1 1 11 1 1 1
1 1 1 1 1 1
1 1 1
1 1 1
1 1 11 1
1 1
1
1
1
1
1
1
1
11
Net % -56 +12 +64 -19 -10 +8
Which of these is the most/least important goal for pharmacare reform?
AllDelegates
Incentives for investment and
innovation
Appropriateness of prescribing
and use
Access to needed Rx for all
Canadians
Choice regarding Rx and/or insurance
Equity in the distribution of Rx
costs
Efficiency in management of Rx expenditures
11111111111111111111111111111111 1 11 1 11 1 11 1 1 1 1
% 0 10 72 10 3 3
1111111111111111111111111111 11 11 11 1 11 1 11 1 1 11 1 1 1
% 5 10 70 0 0 15
111111111111111111111111111111111111 11 11 11 1 11 1 1
% 0 6 82 12 0 0
111111111111111 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 1 1
% 3 23 51 0 3 20
11111111111111111111111111111 1 11 1 11 1 11 1 1 11 1 1 1
% 0 12 68 2 5 12
Academia
Which of these is the most important goal for pharmacare reform?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Incentives for investment and
innovation
Appropriateness of prescribing
and use
Access to needed Rx for all
Canadians
Choice regarding Rx and/or insurance
Equity in the distribution of Rx
costs
Efficiency in management of Rx expenditures
11111111111111 11 11 11 11 11 11 11 11 11 1 1 1 11 1 1 1 11 1 1 1 1
% 52 7 0 7 26 7
111111111 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 1
% 47 0 0 32 16 5
1111111111111111 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 1 11 1 1 1 1
% 50 0 6 19 19 6
111111111111111111111111 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1
% 66 0 0 19 16 0
11111111111 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 1 1 1
% 58 0 3 37 0 3
Academia
Which of these is the least important goal for pharmacare reform?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Canadians pay far too much
Canadians pay more than they should
have toCanadians pay a
reasonable amountCanadians pay too
little Other / I don’t know
11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1
% 31 33 25 0 12
Overall do Canadians pay reasonable prices for patented drugs?
AllDelegates
Canadians pay far too much
Canadians pay more than they should
have toCanadians pay a
reasonable amountCanadians pay too
little Other / I don’t know
11111111111111111111111111111111 1 1 11 1 1 11 1 1 11 1 1 1
% 10 10 71 0 10
111111 11 11 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 1
% 35 46 15 0 4
11111111111111111111 11 11 11 11 11 11 11 11 1 1 11 1 1 11 1 1 1
% 8 62 23 0 8
111111111 11 11 11 11 11 11 11 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1
% 45 29 13 0 13
11 11 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 36 38 8 0 18
Academia
Overall do Canadians pay reasonable prices for patented drugs?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Stronger regulation of list prices paid by all
Single-payer to negotiate system-
wide rebates
Public/private competition for
rebates
Collaboration among public
plans for rebates
Public/private collaboration for
rebatesOther / I don’t
know
1
1
1
11
1
1
11 1 1
1 1 1 1 11 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1
1 1 1
1 1 11 1
1 1
1
1
1
1
1
1
1
Net % -10 +42 -42 +6 -1 +7
Which of these would be the best/worst approach to patented drug pricing?
AllDelegates
Stronger regulation of list prices paid by all
Single-payer to negotiate system-
wide rebates
Public/private competition for
rebates
Collaboration among public
plans for rebates
Public/private collaboration for
rebatesOther / I don’t
know
11111 11 11 1 11 1 11 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 1
% 18 14 11 29 7 21
11111111111111111111111111 11 11 11 1 1 11 1 1 11 1 1 1 1 1
% 4 63 8 8 13 4
11111 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 1
% 8 25 8 8 33 17
11111111 11 11 11 11 1 11 1 1 1 11 1 1 1 11 1 1 1 1 11 1 1 1 1 11 1 1 1 1 1
% 14 36 7 11 21 11
1111111111111111111111111111111111111 11 11 11 1 1 1 1
% 9 82 3 0 3 3
Academia
Which of these would be the best approach to patented drug pricing?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Stronger regulation of list prices paid by all
Single-payer to negotiate system-
wide rebates
Public/private competition for
rebates
Collaboration among public
plans for rebates
Public/private collaboration for
rebatesOther / I don’t
know
1111111111 11 11 11 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 1 1
% 43 4 26 0 17 9
111111111111111111 11 11 11 11 11 11 11 1 11 1 11 1 1 1 11 1 1 1 1
% 5 10 57 5 24 0
1 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 1 1 11 1 1 11 1 1 11 1 1 1
% 40 10 40 0 0 10
1111111111 11 11 11 11 11 11 11 11 11 11 11 11 1 11 1 11 1 1 1 1 1
% 31 4 50 4 8 4
1111111111111111111111 11 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 1
% 13 0 60 10 17 0
Academia
Which of these would be the worst approach to patented drug pricing?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Increase fees for current services
Add new fees for new professional services
Pharmacies should not be compensated Other / I don’t know
111111111 11 11 1
1 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 22 44 28 6
AllDelegates
How should pharmacies be compensated for lost rebates from generic suppliers?
Increase fees for current services
Add new fees for new professional services
Pharmacies should not be compensated Other / I don’t know
11111111111111111111 11 11 11 11 11 11 11 11 11 1 11 1 11 1 1 1
% 7 64 25 4
1111111111111111111 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 1 1
% 9 61 26 4
1111 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 31 38 23 8
111 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 1
% 31 35 31 4
1 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 1
% 34 21 34 10
Academia
How should pharmacies be compensated for lost rebates from generic suppliers?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Separate price-setting by public and
private plans
Regulated price-setting for prices
paid by all
Separate tendering for public and
private drug plans
Single tender for a universal public drug
plan Other / I don’t know
1
1
1
1
1
1
11
1
1
1 11 1 1
1 1 11 1 1 1
1 1 1 1
1 1 1 1
1 1 1 1
11
1
1
1
1
1
1
1
1
11
1
1
Net % -63 +8 -5 +46 +15
Which of these would be the best/worst approach to generic drug pricing?
AllDelegates
Separate price-setting by public and
private plans
Regulated price-setting for prices
paid by all
Separate tendering for public and
private drug plans
Single tender for a universal public drug
plan Other / I don’t know
1111 11 11 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1 1
% 4 32 18 25 21
1111111111111111111111111111111 11 11 11 11 11 11 1 1 1
% 0 16 4 76 4
111111111 11 11 11 11 11 11 11 11 11 11 11 11 11 1 1 11 1 1 11 1 1 1
% 0 8 8 50 33
1111111111111111111111 11 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1 1
% 3 17 7 59 14
1111111111111111111111111111 11 11 11 11 1 11 1 11 1 11 1 1
% 0 17 0 72 10
Academia
Which of these would be the best approach to generic drug pricing?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Separate price-setting by public and
private plans
Regulated price-setting for prices
paid by all
Separate tendering for public and
private drug plans
Single tender for a universal public drug
plan Other / I don’t know
111111111111111111 11 11 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 56 15 7 22 0
1111111111111111111111111111 11 11 1 1 11 1 1 11 1 1 11 1 1 1
% 68 9 9 14 0
111111111111111111111111 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 62 8 15 15 0
11111111111111111111111111111111 11 11 1 1 11 1 1 11 1 1 1
% 73 8 12 8 0
1111111111111111111111111111 11 11 11 11 1 1 11 1 1 11 1 1 1
% 69 8 15 8 0
Academia
Which of these would be the worst approach to generic drug pricing?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Compulsory, with a public plan for high
risk groups
Voluntary, with public coverage of catastrophic costs
Voluntary, with full public coverage for
seniors
Minimal, with full public coverage for
all residents Other / I don’t know
1
1
1
11
1 1
1 1
1 11 1 1
1 1 1 11 1 1 1 1
1 1 1 1 1
1 1 1 1 1
1 1 1 1
1 1 11 1
1
1
1
1
1
1
1
1
1
Net % -48 +14 +4 +27 +3
What would be the ideal/worst role for private insurance after pharmacare reform?
AllDelegates
Compulsory, with a public plan for high
risk groups
Voluntary, with public coverage of catastrophic costs
Voluntary, with full public coverage for
seniors
Minimal, with full public coverage for
all residents Other / I don’t know
111111111 1 11 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1 1
% 21 38 21 17 4
11111111111111111111111111 11 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 0 15 8 65 12
11111 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 1 11 1 1 11 1 1 1
% 0 33 17 42 8
111111111 11 11 11 11 11 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1 11 1 1 1 1
% 6 26 13 42 13
111111111111111111111111 11 11 1 11 1 11 1 11 1 11 1 11 1 1 1
% 0 18 14 64 4
Academia
What would be the ideal role for private insurance after pharmacare reform?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Compulsory, with a public plan for high
risk groups
Voluntary, with public coverage of catastrophic costs
Voluntary, with full public coverage for
seniors
Minimal, with full public coverage for
all residents Other / I don’t know
111111111111111 11 11 11 11 11 11 11 11 11 11 1 11 1 11 1 1 11 1 1 1
% 29 10 5 57 0
1111111111111111111111111 11 11 11 11 1 11 1 11 1 11 1 1 1 1
% 65 17 4 4 9
111111111111111111111111 11 11 11 11 1 1 11 1 1 11 1 1 11 1 1 1
% 64 9 9 18 0
111111111111111111111111111 1 11 1 11 1 1 11 1 1 11 1 1 1 1
% 64 12 12 4 8
11111111111111111111 11 11 11 11 1 11 1 11 1 1 11 1 1 11 1 1 1 1
% 58 19 12 4 8
Academia
What would be the worst role for private insurance after pharmacare reform?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Michael McBane, Canadian Health
Coalition
Jordan Bateman, CDN Taxpayers
FederationAnna Reid, Canadian Medical Association
Marc Collison, Heart and Stroke Foundation
Dan Clow, GSK Canada
1 11 11 11 11 11 11 11 1 11 1 11 1 11 1 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1
% 32 9 32 11 17
Whose vision for pharmacare most closely aligns with your own?
AllDelegates
Michael McBane, Canadian Health
Coalition
Jordan Bateman, CDN Taxpayers
FederationAnna Reid, Canadian Medical Association
Marc Collison, Heart and Stroke Foundation
Dan Clow, GSK Canada
1111111111111111111 11 11 1 11 1 1 11 1 1 11 1 1 11 1 1 11 1 1 1 1
% 4 18 11 14 54
111111111111111111111 11 11 11 11 11 11 11 11 1 1 1 11 1 1 1 1
% 61 6 22 6 6
1 11 11 11 11 11 11 11 11 11 1 11 1 11 1 11 1 11 1 11 1 11 1 1 1 11 1 1 1 1
% 35 6 35 18 6
11111111111 11 11 11 11 11 1 11 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1
% 23 10 43 10 13
111 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 1 1 1 11 1 1 1 1
% 44 6 39 6 6
Academia
Whose vision for pharmacare most closely aligns with your own?
RxIndustry
HealthProfessions
Non-profits
Public Sector
Continue to believe reform unnecessary or
infeasible
More firmly believe reform unnecessary or
infeasibleContinue to believe reform is necessary
More firmly believe reform is necessary
11111
1 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 1
1 1 1 11 1 1 1
% 4 4 41 52
How did this conference affect your thinking about the need for pharmacare reform?
AllDelegates
Lack of clear vision
Cost of reforming system
Low public engagement
Opposition from interests
Lack of political will
Poor federal-provincial relations
1111
1 11 11 11 1
1 1 11 1 11 1 11 1 1 11 1 1 1 11 1 1 1 11 1 1 1 11 1 1 1 1 11 1 1 1 1 1
% 17 4 9 26 33 12
What is the most significant barrier to pharmacare reform?
AllDelegates
